Vita 34 AG: Successful Annual General Meeting with Notable Approval of Shareholders

Vita 34 AG / Key word(s): AGM/EGM

25.07.2013 / 12:16

Vita 34 AG: Successful Annual General Meeting with Notable Approval of Shareholders

– Presence of capital stock totaled 32.78%.

– Management Board reported on fiscal year 2012 and confirmed positive outlook for 2013

– Dr. Hans-Georg Giering elected as new Supervisory Board member

Leipzig, July 25, 2013 – Vita 34 AG (WKN A0BL84), Europe’s oldest private stem cell bank and a specialist for cryo-preservation, conducted its 2013 Annual General Meeting successfully in Leipzig today. Here, the presence of capital stock represented was 32.78%. The company reported on the development of business in the prior fiscal year 2012, and looked optimistically towards the future.

Within the scope of the Annual General Meeting all agenda items were accepted by a large majority of the shareholders present. Apart from a change in the by-laws regarding the corporate purpose of Vita 34 AG in the wake of the merger with BioPlanta GmbH, which became effective on November 30, 2012, when it was recorded in the corporate register, among other things new elections to the Supervisory Board were on the agenda. Supervisory Board member Dr. Uwe Marx resigned his position effective today. Per nomination, Dr. Hans-Georg Giering was elected as his successor. All of the Supervisory Board members and the Management Board in office in fiscal year 2012 were granted discharge.

Dr. André Gerth, Chairman of the Management Board of Vita 34 AG, explained to the shareholders the measures initiated in 2012 for increasing profitability, and took positive stock of the latest business developments: ‘The cost reduction measures contributed significantly to the improvement in the Vita 34 fiscal position in the first half-year 2013. We will continue to expand our market presence in Europe with local cooperative sales ventures and subsidiaries, and solidify our market leadership by introducing new products.’

Dr. Gerth also confirmed the prognosis for fiscal year 2013: ‘We expect a clear increase in operating profit (EBITDA) to at least EUR 1 million in the current year. We are very pleased that EBITDA in the first half-year 2013 is already higher than in the prior year’s period.’

Company Profile

Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider, offers collection logistics, preparation and storage of umbilical cord blood. The basis for its successful work is an outstanding position in the technological segment of cryo-preservation. Here, cells and tissues are preserved alive at temperatures around minus 190 degrees Celsius, and can be used if needed in the context of medical treatment. Parents of more than 95,000 children are already taking advantage of this offering and have provided for their children with a stem cell deposit at this Leipzig company.

End of Corporate News

25.07.2013 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at and

222834  25.07.2013